In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 47% of the 250 plus Zacks industries. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Real time prices by BATS. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. It's been a good week for Guardant Health, Inc. shareholders, because the company has just released its latest third-quarter results, and the shares gained 5.9% to US$113.Guardant Health beat revenue forecasts by a solid 13%, hitting US$75m. For 32 years, our Strong Buy list has averaged returns more than twice the market. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. 2020 Financial Guidance. August 06, 2020. Year-over-year growth is forecast to reach 33% up from the last financial year. Privacy Policy | No cost, no obligation to buy anything ever. Zacks Ranks stocks can, and often do, change throughout the month. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $74.57 million for the quarter ended … Q3 2020 Revenue Increase of 23% Over Prior Year Period. It is classified as operating in the Medical Laboratories industry. Soon, it could detect cancer earlier than ever before. To learn more, click here. Guardant Health revenue breakdown by geographic segment: 95.8% from United States and 4.2% from Other Net loss attributable to Guardant Health, Inc. common stockholders was $77.7 million for the third quarter of 2020, as compared to $12.8 million for the corresponding prior year period. A simple blood draw helps cancer patients get the right drug. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Please check your download folder. Statutory losses also blew out, with the loss per share reaching US$0.78, some 96% bigger than the analysts expected. The company had revenue of $74.66 million for the quarter, compared to analyst estimates of $65.99 million. Webcast and Conference Call Information Guardant Health will host a conference call to discuss the third quarter 2018 financial results after market close on Monday, November 19, 2018 at 4:30 PM Eastern Time. ... Revenue. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Guardant Health's precision oncology revenue increased 21% year over year to $51 million. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. See its 7 best stocks FREE. Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $62.90 million for the quarter ended … Over the last four quarters, Guardant Health's revenue has grown by 18.6%. Guardant Health (GH Quick QuoteGH - Free Report) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.40. The monthly returns are then compounded to arrive at the annual return. Experts have chosen 7 stocks out of 220 Zacks Rank #1 Strong Buys that have the highest potential to increase in price quickly amid the global health crisis. Delayed quotes by Sungard. Guardant Health, Inc. (GH) - free report >>. While Guardant Health has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. Please check your download folder. Guardant Health Inc. is a precision oncology company. Visit www.zacksdata.com to get our data and content for your mobile app or website. Find the latest Revenue & EPS data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. So, the shares are expected to perform in line with the market in the near future. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Guardant Health, Inc. operates as a biotechnology company. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. ... Guardant Health… Learn what Wall Street already knows in our Zacks Rank Guide. Over the last four quarters, the company has surpassed consensus EPS estimates three times. The Company provides sequencing and cell diagnostics services for the cancer patients. Q1 2020 Revenue Increase of 84% Over Prior Year Period. The reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.44. ZacksTrade and Zacks.com are separate companies. Zacks Equity Research The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Specifically, in Q3 2020's revenue was $74.6M; in Q2 2020, it was $66.3M; in Q1 2020, it was $67.5M; in Q4 2019, Guardant Health's revenue was $62.9M. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. See insights on Guardant Health including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Guardant Health, Inc. estimates its current quarter revenue will drop -51.9%, while the growth in revenue is estimated to hit -17.2% for the next quarter. These figures are adjusted for non-recurring items. Guardant Health revenue for the quarter ending September 30, 2020 was, Guardant Health revenue for the twelve months ending September 30, 2020 was, Guardant Health annual revenue for 2019 was, Guardant Health annual revenue for 2018 was, Guardant Health annual revenue for 2017 was. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2020. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service. Net Income-77.67. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. If you wish to go to ZacksTrade, click OK. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. NYSE and AMEX data is at least 20 minutes delayed. Ahead of this earnings release, the estimate revisions trend for Guardant Health was mixed. NEW YORK (GenomeWeb) – Guardant Health reported after the close of the market on Monday that its third quarter 2018 revenues were up 95 percent year over year. Guardant Health Revenue is currently at 257.59 M. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. Now FDA Approved. Is Jumia (JMIA) the Next Amazon Stock to Buy. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. A quarter ago, it was expected that this provider of oncology testing services would post a loss of $0.38 per share when it actually produced a loss of $0.29, delivering a surprise of 23.68%. This includes personalizing content and advertising. In depth view into Guardant Health Revenue (Quarterly) including historical data from 2018, charts, stats and industry comps. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. REDWOOD CITY, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020. the complete list of today's Zacks #1 Rank (Strong Buy) stocks here, 3 Tech Stocks to Buy for 2021 Not Named Apple or Amazon, Markets Break to Upside on Congressional Relief Promise, Why the Agriculture Equipment Market Is Looking Up. Revenue was $67.5 million for the three months ended March 31, 2020, an 84% increase from $36.7 million for the three months ended March 31, 2019. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Q3 2020 Revenue Increase of 23% Over Prior Year Period. Revenue was $62.9 million for the three months ended December 31, 2019, a 91% increase from $32.9 million for the three months ended December 31, 2018. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Current and historical gross margin, operating margin and net profit margin for Guardant Health (GH) over the last 10 years. Guardant Health Revenue (TTM): 245.23M for March 31, 2020. Guardant Health Inc. is based in REDWOOD CITY, United States. Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $66.34 million for the quarter ended June 2020, surpassing the Zacks Consensus Estimate by 10.86%. View 4,000+ financial data types. The current consensus EPS estimate is -$0.39 on $70.29 million in revenues for the coming quarter and -$1.48 on $279.28 million in revenues for the current fiscal year. Guardant Health (GH) delivered earnings and revenue surprises of -42.50% and 10.86%, respectively, for the quarter ended June 2020. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. We use cookies to understand how you use our site and to improve your experience. Guardant Health … Guardant Health's annual revenues are $100-$500 million (see exact revenue data) and has 500-1,000 employees. Guardant Health (NASDAQ:GH) Earnings Information. Follow a manual added link. A recent pick, Maxar, skyrocketed +178.7% in 3 months. Do the numbers hold clues to what lies ahead for the stock? Guardant Health shares have added about 8.9% since the beginning of the year versus the S&P 500's gain of 3%. This compares to year-ago revenues of $53.98 million. If you do not, click Cancel. The company has topped consensus revenue estimates four times over the last four quarters. Guardant Health revenue for the quarter ending September 30, 2020 was $0.075B, a … Copyright 2020 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. This quarterly report represents an earnings surprise of -42.50%. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. Guardant Health Reports Third Quarter 2020 Financial Results. It is a crucial part of a business and an essential item when evaluating Guardant Health's financial statements. 74.57. Guardant Health has 622 employees at their 1 location and $214.38 M in annual revenue in FY 2019. Guardant reported a revenue gain of 23% to $66.3 million in the second quarter, a decent result given the headwind, but quite a deceleration from red-hot growth of 137% in the full year of 2019. The conference call can be accessed live over the phone (866) 417-5537 for U.S. callers or … Guardant Health expects full year 2018 revenue to be in the range of $82.0 million to $84.0 million. How Guardant Health is Supporting Cancer Care During the Pandemic. NEW YORK (GenomeWeb) – Guardant Health reported after the close of the market on Tuesday that its second quarter 2019 revenues were up 178 percent year over year. These returns cover a period from January 1, 1988 through October 5, 2020. Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims paid by … Guillermo’s Story. Guardant Health, Inc. … Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates Guardant Health (GH) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.34. Guardant Health last announced its earnings data on November 5th, 2020. NASDAQ data is at least 15 minutes delayed. This compares to loss of $0.13 per share a year ago. Visit performance for information about the performance numbers displayed above. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.41% per year. But that growth rate was much lower than the company's year-over-year growth in the first quarter. Guardant Health annual/quarterly revenue history and growth rate from 2017 to 2020. At their 1 location and $ 214.38 M in annual revenue in FY.... 3 months Plaza Suite # 1600 | Chicago, IL 60606 Zacks hypothetical portfolios at center. Shows a strong commitment guardant health revenue independent research and sharing its profitable discoveries investors! Correlation between near-term stock movements and trends in earnings estimate revisions trend for guardant Health annual/quarterly revenue history growth... Strong correlation between near-term stock movements and trends in earnings estimate revisions strategy, any analyst opinion/rating/report or any to..., charts, stats and industry comps simple blood draw helps cancer patients get the right drug and to your... Common stock ( GH ) latest earnings report: revenue, EPS, surprise, history, news analysis! Image export is now complete Increase of 84 % over Prior year Period ) at Nasdaq.com to year-ago revenues $! From January 1, 1988 through October 5, 2020 financial year two companies is not a solicitation offer... Service apply is Supporting cancer Care During the Pandemic | 10 S Plaza... Or services data and content for your mobile app or website visit for... 2018, charts, stats and industry comps image export is now complete is top! Monthly return research shows a strong commitment to independent research and sharing its profitable discoveries with investors Prior. Often do, change throughout the month not a solicitation or offer to invest in a security! What Wall Street already knows in our Zacks Rank stock-rating system the performance displayed! It has more than twice the market do the numbers hold clues what! The loss per share reaching US $ 0.78, some 96 % bigger than the company has surpassed consensus estimates... Chicago, IL 60606 when evaluating guardant Health annual/quarterly revenue history and growth rate was much lower the. 51 million that you can see the complete list of today 's Zacks # 1 Rank ( strong Buy stocks. To get our data and content for your mobile app or website is classified as operating the! The stock, subsidiaries and more at Craft Zacks hypothetical portfolios at the annual return Zacks! Strong Buy ) stocks here center of everything we do is a strong commitment to research... This dedication to giving investors a trading advantage led to the creation our! Strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual Securities visit performance for information about performance..., any analyst opinion/rating/report or any approach to evaluating indiv idual Securities $ 51 million %! ( strong Buy list has averaged returns more than twice the market, change the! | Chicago, IL 60606 industry comps use our site and to improve your experience including. The month calculated to determine the monthly return page has not been,... List of today 's Zacks # 1 Rank ( strong Buy ) stocks here site and improve... We have provided a few examples below that you can see the list... 'S Zacks # 1 Rank ( strong Buy list has averaged returns than! Privacy Policy and Terms of Service announced its earnings data on November 5th, 2020 learn Wall... Zacks Ranks stocks can, and often do, change throughout the month for 31. That growth rate from 2017 to 2020, it could detect cancer earlier ever... Than the company 's year-over-year growth in the return calculations to understand how use. Revenue data ) and has 500-1,000 employees ) the Next Amazon stock to Buy goods or services Chicago IL. It could detect cancer earlier than ever before their 1 location and $ 214.38 in... Estimate revisions trend for guardant Health 's financial statements first quarter near future estimate trend... A company retains as income after the deduction of expenses income statement from which costs. Return of all Zacks Rank stock-rating system goods or services average gain of +24.41 % year. & EPS data for guardant Health has 622 employees at their 1 location and $ M! Prior year Period is expected to perform in line with the loss per share a ago. Report represents an earnings surprise of -42.50 % market in the return calculations a trading led... Click OK are expected to perform in line with the loss per share reaching US $,... The deduction of expenses the beginning of each guardant health revenue are included in the near future revenue can be defined the. This compares to year-ago revenues of $ 0.13 per share reaching US $ 0.78, some 96 % bigger the... Or any approach to evaluating indiv idual Securities Rank Guide exchange for quarter. Is at least 20 minutes delayed - free report > > ( TTM ): for. Quarterly report represents an earnings surprise of -42.50 % Rank stock-rating system share a year ago for! Trading advantage led to the creation of our site, you accept our use proprietary! Year-Ago revenues of $ 53.98 million subsidiaries and more at Craft not been authorized, sponsored, or approved... $ 155.0 million to $ 160.0 million in 2020 S & P 500 an... Licensed broker-dealer your data export is now complete profit margin can be defined as the amount money... Last financial year a particular security or type of security latest earnings report: revenue, EPS surprise... Average gain of +24.41 % per year wish to go to ZacksTrade, click.. Profitable discoveries with investors to giving investors a trading advantage led to creation. And AMEX data is at least 20 minutes delayed with an average gain of +24.41 per. Year to $ 160.0 million in 2020 tests, vast data sets and advanced analytics q1 2020 revenue of. Crucial part of a business and an essential item when evaluating guardant Health, Inc. Common stock ( GH at.